Ionis Pharmaceuticals Inc. saw a price increase of 5.51% as it reached a 52-week high, reflecting strong investor interest in the stock.
This surge is attributed to the successful Phase 3 trial results for Bepirovirsen in chronic hepatitis B treatment, demonstrating a significant functional cure rate. The trials involved over 1,800 patients across 29 countries, indicating a major advancement in treatment options and a strong market potential for the drug, which could address the needs of over 250 million people globally.
The positive results not only enhance Ionis's reputation in the biopharmaceutical sector but also position the company for substantial financial benefits, including up to $150 million in milestone payments from its collaboration with GSK, further solidifying its market presence.
Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 92.67 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 92.67 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.920
Low
65.00
Averages
92.67
High
110.00
Current: 81.920
Low
65.00
Averages
92.67
High
110.00
Barclays
Overweight
initiated
$95
2026-01-27
New
Reason
Barclays
Price Target
$95
AI Analysis
2026-01-27
New
initiated
Overweight
Reason
Barclays assumed coverage of Ionis Pharmaceuticals with an Overweight rating and $95 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Wells Fargo
NULL
to
Overweight
upgrade
$82 -> $100
2026-01-05
Reason
Wells Fargo
Price Target
$82 -> $100
2026-01-05
upgrade
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Ionis Pharmaceuticals to $100 from $82 and keeps an Overweight rating on the shares. Following a strong 2025, the firm sees further value creation on multiple catalysts in 2026, including Phase 3 readouts for bepirovirsen in cHBV, pelacarsen in Lp(a) and WAINUA in ATTR-CM.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IONS
Unlock Now
RBC Capital
Luca Issi
Outperform
maintain
$82 -> $95
2025-12-17
Reason
RBC Capital
Luca Issi
Price Target
$82 -> $95
2025-12-17
maintain
Outperform
Reason
RBC Capital analyst Luca Issi raised the firm's price target on Ionis Pharmaceuticals to $95 from $82 and keeps an Outperform rating on the shares. The company is poised to successfully transition to a fully integrated commercial organization as its Tryngolza is off to a good start in FCS, and the firm believes that recent data in sHTG will open up a much broader opportunity given a total addressable market of 1M patients in the US alone, the analyst tells investors in a research note.
BofA
Jason Gerberry
Buy
maintain
$86 -> $97
2025-12-09
Reason
BofA
Jason Gerberry
Price Target
$86 -> $97
2025-12-09
maintain
Buy
Reason
BofA analyst Jason Gerberry raised the firm's price target on Ionis Pharmaceuticals to $97 from $86 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm's CNS Therapeutics Conference.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
